Linked Life Data

15474322

Source:http://linkedlifedata.com/resource/pubmed/id/15474322

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-10-11
pubmed:abstractText
We examined the activity of arbekacin, daptomycin, tigecycline, and vancomycin against various Staphylococci isolates with glycopeptide-intermediate (n = 25) and heterogeneous susceptibilities (n = 22) (GISS and hGISS). The minimum inhibitory concentrations (MIC) of each antimicrobial was evaluated in time-kill experiments by using 4 randomly selected GISS isolates tested at 2 and 4 times their respective MIC. The MIC(90) microg/mL ranges for arbekacin, daptomycin, tigecycline, and vancomycin were 2 (0.25-4), 1 (0.0625-2), 0.5 (0.0625-2), and 8 (4-8), respectively. Time kill at 2 times the MIC demonstrated a mean log(10) colony forming units (CFU)/mL change of -2.98 +/- 0.708, -3.6 +/- 0.509, -2.48 +/- 0.647, and +1.14 +/- 0.1 arbekacin, daptomycin, tigecycline, and vancomycin, respectively. At 4 times the MIC, significant activity for all compounds was noted with a log(10) CFU/mL decrease range from 3.68 to 2.74 +/- 0.66. Overall, all the antimicrobials tested (with the exception of vancomycin) exhibited significant in vitro activity against GISS. These compounds may offer therapeutic options for the treatment of GISS.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0732-8893
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-30
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline.
pubmed:affiliation
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
pubmed:publicationType
Journal Article, Comparative Study